Veradermics reports preliminary cash of $390.8M as of March 31, 2026

Veradermics, Inc

2026-Q1 EPS reported -$1.32

Preliminary unaudited cash, cash equivalents and marketable securities total approximately $390.8 million as of March 31, 2026.
This amount is preliminary and subject to change upon completion of quarterly closing procedures.
Auditors Deloitte & Touche LLP have not audited or reviewed this preliminary data.
No other financial results (revenue, earnings) were disclosed in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.